Conjugate Vaccines Market worth $21.77 billion by 2030
The report "Conjugate Vaccines Market by Disease (Pneumococcal, DTP, Meningococcal Disease), Type (Monovalent, Multivalent), End User (Adult, Pediatric) - Forecast to 2030" is projected to grow from USD 15.25 billion in 2025 and to reach USD 21.77 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 7.4% during the forecast period.
Browse 420 market data Tables and 40 Figures spread through 380 Pages and in-depth TOC on "Conjugate Vaccines Market by Disease (Pneumococcal, DTP, Meningococcal Disease), Type (Monovalent, Multivalent), End User (Adult, Pediatric) - Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/conjugate-vaccine-market-199230303.html
The conjugate vaccines market is experiencing growth, driven by several key factors, including strong disease burden in target populations and rising inclusion in national immunization programs.
Pneumococcal disease segment accounted for the largest share of the conjugate vaccines market by disease indication in 2024.
By disease indication, the conjugate vaccines market is divided into pneumococcal disease, DTP, meningococcal disease, and other disease indications. In 2024, pneumococcal disease accounted for the largest market share, driven by high rates of invasive pneumococcal disease (IPD) in both pediatric and adult populations. This increase is supported by routine recommendations for vulnerable groups provided by the CDC/ACIP schedules. Additionally, ongoing advancements in multivalent vaccine formulations and a heightened awareness of the fatal risks associated with pneumonia and sepsis are contributing to a growing global demand for pneumococcal vaccines.
Pediatric vaccines are estimated to register the fastest growth in the conjugate vaccines market by end user during the forecast period.
The market is divided by end user into pediatric vaccines and adult vaccines. During the forecast period, the pediatric segment is expected to be the fastest-growing in the conjugate vaccines market. This growth is driven by routine childhood immunization programs and the high prevalence of vaccine-preventable diseases among infants and young children. Strong government support, mandatory vaccination schedules, and increasing awareness of the importance of preventing diseases at an early age continue to boost the demand for conjugate vaccines in pediatric populations.
North America accounted for the largest regional share in the conjugate vaccines market in 2024.
The market for conjugate vaccines, by region, is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America accounted for the largest share in the conjugate vaccines market, driven by well-established immunization programs, high healthcare spending, and the strong presence of major vaccine manufacturers. Favorable reimbursement policies, early adoption of advanced vaccines, and robust government initiatives for disease prevention also contribute to the region’s leadership in this market.
Key players in the conjugate vaccines market include Pfizer Inc. (US), Merck & Co., Inc. (US), GSK (UK), Sanofi (France), Serum Institute of India (India), Daiichi Sankyo Company Limited (Japan), Panacea Biotec (India), and Biological E. Limited (India).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Conjugate Vaccines Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
